Processing

Please wait...

Settings

Settings

Goto Application

1. WO2012144649 - METHOD FOR MODULATING CYTOKINE ACTIVITY

Publication Number WO/2012/144649
Publication Date 26.10.2012
International Application No. PCT/JP2012/061004
International Filing Date 18.04.2012
IPC
A61K 31/5575 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
557Eicosanoids, e.g. leukotrienes
5575having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 31/558 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
557Eicosanoids, e.g. leukotrienes
558having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
A61P 1/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
04for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 37/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
CPC
A61K 31/5575
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
557Eicosanoids, e.g. leukotrienes ; or prostaglandins
5575having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 31/558
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
557Eicosanoids, e.g. leukotrienes ; or prostaglandins
558having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 1/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
04for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
Applicants
  • SUCAMPO AG [CH]/[CH] (AllExceptUS)
  • UENO, Ryuji [JP]/[US] (UsOnly)
Inventors
  • UENO, Ryuji
Agents
  • SAMEJIMA, Mutsumi
Priority Data
61/476,99219.04.2011US
61/489,51624.05.2011US
61/537,30521.09.2011US
61/548,45818.10.2011US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHOD FOR MODULATING CYTOKINE ACTIVITY
(FR) PROCÉDÉ DE MODULATION DE L'ACTIVITÉ DES CYTOKINES
Abstract
(EN)
The present invention relates to a method for modulating cytokine activity, immunomodulation or treating esophagitis comprising an administration of a fatty acid derivative to a mammalian subject. The present invention also relates to a composition for modulating cytokine activity, immunomodulation or treating esophagitis comprising a fatty acid derivative.
(FR)
La présente invention concerne un procédé de modulation de l'activité des cytokines, d'immunomodulation ou de traitement d'une œsophagite qui comprend l'administration d'un dérivé d'acide gras à un sujet mammifère. La présente invention concerne en outre une composition de modulation de l'activité des cytokines, d'immunomodulation ou de traitement d'une œsophagite qui comprend un dérivé d'acide gras.
Latest bibliographic data on file with the International Bureau